Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in Germany

Value in Health

Volumn 5, Issue 5, 2002, Pages 398-404

  Wagenpfeil, Stefan ^a   Neiss, Albrecht ^a   Goertz, Anita ^b   Reitberger, Ursula ^c   Stammer, Holger ^b   Spannheimer, Andrea ^c   Liebl, Andreas ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c Kendle International Inc   (Germany)

^d Fachklinik Bad Heilbrunn   (Germany)

Author keywords

Bootstrap methods; Costs; Diabetes complications; Diabetes epidemiology

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; DATA ANALYSIS; DIET THERAPY; DRUG COST; FEMALE; GENERAL PRACTICE; GERMANY; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SOCIOECONOMICS;

EID: 0036741874     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.55136.x     Document Type: Article

References (26)

1. King H, Zimmet P. Trends in the prevalence and incidence of diabetes: non-insulin-dependent diabetes mellitus. World Health Stat Q 1988;41: 190-6.
2. McCarty D, Zimmet P. Diabetes 1994-2010: Global Estimates and Projections. Melbourne: International Diabetes Institute, 1994.
3. Jönsson B. The economic impact of diabetes. Diabetes Care 1998;21:C7-10.
4. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus. J Clin Endocrinol Metab 1992;78: 809A-F.
5. Jönsson B. The cost of diabetes and the cost-effectiveness of interventions. In: Abshagen, U, Münnich, FE, eds., Costs of Illness and Benefits of Drug Treatment, 51-7. Munich/Bern/Wien/San Francisco: Zuckschwerdt-Verlag, 1990.
6. European Diabetes Policy Group. Guidelines for diabetes care: a desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:1-35.
7. Liebl A, Neiss A, Spannheimer A, et al. Complications, co-morbidity and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2® study. Exp Clin Endocrinol Diabet 2002;110:10-6.
8. Liebl A, Neiss A, Spannheimer A, et al. Kosten des typ-2-diabetes in Deutschland - ergebnisse der CODE-2® studie. Deutsche Med Wochenschrift 2001;126:585-9.
9. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-200.
10. Patel JK, Read CB. Handbook of the Normal Distribution (2nd ed). New York/Basel/Hong Kong: Dekker, 1996.
11. Statistisches Bundesamt. Gesundheitsbericht für Deutschland: gesundheitsberichterstattung des bundes. Stuttgart: Metzler-Poeschel, 1998.
12. Hauner H, von Ferber L, Köster I. Schätzung der diabeteshäufigkeit in der bundesrepublik Deutschland anhand von krankenkassendaten: sekundärdatenanalyse einer repräsentativen stichprobe AOK-versicherter der stadt Dortmund. Dtsch Med Wschr 1992;117:645-50.
13. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat 1979;7:1-26.
14. Diaconis P, Efron B. Statistik per Computer: der Münchhausen-Trick. Spektrum der Wissenschaft, 1983 Juli:56-71.
15. Manly BFJ. Randomization, Bootstrap and Monte Carlo Methods in Biology (2nd ed). London: Chapman & Hall, 1998.
16. Karian ZA, Dudewicz EJ. Modern Statistical, Systems, and GPSS Simulation (2nd ed.). Boca Raton, FL/London/New York/Washington, DC: CRC Press, 1999.
17. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the nonparametric bootstrap. Stat Med 2000;19:3219-36.
18. Efron B, Tibshirani R. An Introduction to the Bootstrap. Boca Raton, FL/London/New York: Chapman & Hall/CRC Press, 1998.
19. Nuijten MJC. Measuring sensitivity in pharmacoeconomic studies. Pharmacoeconomics 1999;16: 33-41.
20. Statistical Yearbook 2000 for the Federal Republic of Germany. Section 18.3. Statistisches Bundesamt. Stuttgart: Metzler-Poeschel, 2000.
21. Wagenpfeil S, Stammer H, Neiss A, et al. Use of Bootstrap in a Cost-of-Illness Study to Derive Accuracy of Estimates. In: Hay J, Rindress D, et al., eds., ISPOR Vth Annual International Meeting. Value Health 2000;3:338-9.
22. Liebl A, Goertz A, Henkel B, Spannheimer A. Kostet der Zucker 20 Milliarden pro Jahr? MMW-Fortschr Med 2000;142:39-42.
23. Liebl A, Spannheimer A, Reitberger U, et al. Aktuelles diabetesmanagement für patienten mit typ 2 diabetes in Deutschland: ergebnisse CODE-2® studie. Diabet Stoffwechsel 2002;11:55-61.
24. Spannheimer A, Goertz A, Reitberger U, et al. Dealing with co-morbidity and rare complications in a diabetes type 2 cost of illness study. Value Health 1999;2:370.
25. Ramsey SD, Newton K, Blough D, et al. Patient-level estimates of the cost of complications in diabetes in a managed-care population. Pharmacoeconomics 1999;16:285-95.
26. Pibernik-Okanović M, Szabo S, Metelko Ž. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 1998;14: 201-7.